Transgene SA announced that the Board has appointed Dr. Alessandro Riva, MD, as the Company's new Chairman to accelerate the development of Transgene's innovative immunotherapy portfolio. Alessandro Riva has been the Chairman of the Company's Board of Directors since May 2022, will replace Hedi Ben Brahim, effective June 1st, 2023. Dr. Riva has an outstanding track record in the pharmaceutical and biotechnology industry, leading to the approval of innovative oncology treatments in the US and in Europe.

He aims to work closely with Transgene's Board of Directors and the whole organization to realize the potential of the Company's product portfolio to benefit patients with solid tumors. Hedi Ben Brahim will retire from the CEO position, which he has held since January 2021, and will stay on as a strategic advisor until the transition is complete. Dr. Riva has nearly 30 years' experience in the Life Sciences industry.

He was CEO of Intima Bioscience which specializes in cell therapies for solid cancers and was previously CEO of Ichnos Sciences. Dr. Riva was also Executive Vice President (EVP), Global Head of Oncology Therapeutics and Cell & Gene Therapy at Gilead Sciences, where he was instrumental in the acquisition of Kite Pharma and led its integration and growth. He also managed the US and EU approvals of Yescarta, the first approved CAR-T cell therapy for adult patients with diffuse large B cell lymphoma.

Prior to Gilead, Dr. Riva was EVP, Global Head of Oncology Development and Medical Affairs at Novartis Pharmaceuticals. Dr. Riva currently serves on the Boards of BeiGene and Century Therapeutics. He received his bachelor's degree in medicine and surgery from the University of Milan and a certificate board in oncology and hematology from the same institution.